Elligo Health Research, a healthcare-enabling research organization, is launching their System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities.
Elligo’s SOAR model expands patient access to reach diverse patient populations that typically don’t have access to clinical research as a care option. The solution drives efficiency by enabling direct data from source to submission and full remote site access, empowering patients, physicians, and sponsors to conduct more trials efficiently and faster in traditional and decentralized models.
“We are extremely excited to launch our tech-enabled solution created to keep the patient and the physician at the heart of its design, while providing sponsors transparency,” said John Potthoff, PhD, CEO of Elligo. “Our goal has always been to provide all patients with access to research as a healthcare option, which is important now more than ever as we navigate the future of clinical research.”
SOAR aims to adhere to regulations and improves data quality while decreasing resource requirements and costs associated with clinical research. Paired with technology-enabled services and personnel, this model accelerates research without compromising quality and integrity. This provides a pathway to either use traditional research sites, DCTs, or hybrid trials, seamlessly moving between options without causing disruption for any stakeholders. This modernizes clinical research for a new paradigm in a new age of clinical research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.